The STEP (Semaglutide Treatment Effect in People with obesity) trials, which evaluated semaglutide for weight management, documented gallbladder disorders in approximately 2.6% of participants receiving the medication versus 1.2% in the placebo group
It is the result of complex interactions between biological, environmental, and psychological factors
Vikrant Shrotriya, Managing Director, Novo Nordisk India, says, The burden of MASH continues to rise in India, but treatment options are still severely limited
Antioxidative and clinical effects of high-dose N-acetylcysteine in fibrosing alveolitis
Within a medical setting, every dosage is expertly titrated
The rapid delivery of these nutrients can lead to improved hydration, enhanced immune function, as well as increased energy levels